prof. Karen Geboes (MD, PhD)

Prof. Dr. Geboes focuses on all tumors of the gastro-intestinal system and the development of new treatments for these disorders. Prof. Dr. Geboes has specific expertise in neuroendocrine tumors and gastrointestinal stromal tumors. She focusses on follow up of patients with hereditary cancer syndromes and somatic testing (NGS) of tumors (in national tumor boards and ComPerMed) as wel as pharmacogenetics (with eg the national consensus paper on DPD testing). She also has a specific interest in early introduction of palliative care. Dr Geboes is also active in several multidisciplinary teams for digestive oncology, at UZ Gent and beyond. She participates in the Phase I steering committee and is involved in the Immuno-Oncology Network (ION).
 

K. Geboes studied medicine at KU Leuven where she also obtained her doctorate. She was trained as a gastroenterologist at the UZ Leuven, and specialized in digestive oncology at the university hospital of Nantes. She also taught at the university.
Prof. dr. Dr Karen Geboes is head of the department of Gastrointestinal and intestinal diseases at UZ Gent and professor at Ghent University. She is associate editor of Acta Gastro-Enterologica Belgica and Acta Clinica Belgica.
 

• dr. Eduard Callebout (MD) – co-investigator
• dr. Suzane Ribeiro (MD) – co-investigator
• dr. Clara Leyns (PhD) - post-doctoral fellow
   

• Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125.
• Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur). Acta Clin Belg. 2021; 11:1-7
• Surveillance recommendations for patients with Lynch syndrome and FAP : a monocentric study. Acta Gastroenterol Belg. 2020; 83(3): 399-405.
• Histopathological Revision for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms in Expert Centers: Does it Make the Difference? Neuroendocrinology. 2020 Mar 11. doi: 10.1159/000507082
• A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, adminstered intravenously to patients with epithelial solid tumors (EVOLVE). J Immunother Cancer. 2019 Jan 28;7(1):20.
• Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile. Oncotarget. 2018; 9(38): 25216-25224. 
• Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor. Oncotarget. 2018; 9(25): 17756-17769. 
• Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases. Eur J Surg Oncol. 2018; 44(7): 1069-1077.
• Effect of early and systematic integration of palliative care in patients with advanced cancer: a randomised controlled trial. Lancet Oncol. 2018; 19(3): 394-404.
• Pathologic Assessment of Rectal Carcinoma after Neoadjuvant Radio(chemo)therapy: Prognostic Implications. Biomed Res Int. 2015; 574540. 
   

• Lab address: Gastro-enterologie en hepatologie, campus UZ Gent, entrance 12 (K12), route 1325
• UZ Ghent website
• member of Vlaamse Vereniging voor Gastro-enterologie (VVGE)
• member of Belgian Group of Digestive Oncology (BGDO), secretary
• member of Erkenningscommissie maag- en darmziekten
• member of International Biliary Tract Cancer Collaborators (IBTCC)
• member of European Neuroendocrine Tumor Society (ENETS)
• member of European Organisation for Research and Treatment of Cancer (EORTC)
• member of European Society of Medical Oncology (ESMO)
• member of European Society of Digestive Oncology (ESDO)
• member of American Society of Clinical Oncology (ASCO)
• member of End-of-Life Care Research Group VUB & UGent
• member of REPOS (Research and Expertise Group for Psychosocial Oncology and Survivorship)
• Prof. Geboes is interested to receive invitations for presentations or talks